Conditions: Cystic Fibrosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7
Healthy volunteers: no

Brief summary:
The purpose of the study is to examine if a specific drug called losartan (Cozaar ®), generally used to treat high blood pressure and to protect kidneys from damage in patients suffering from Diabetes Mellitus, will have any effect on the nasal inflammation in patients with cystic fibrosis (CF). The study will be performed at the Pulmonary Division at the University of Miami, Cincinnati Children's Medical Hospital Center, University of Kansas Medical Center and University of Alabama-Birmingham.

Detailed description:

Arms:
arm 1: Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed). arm 2: Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.

Interventions: intervention 1: Losartan intervention 2: placebo
Intervention descriptions: intervention 1: 25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12. intervention 2: Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.

Protocol document:
Prot_SAP_000.pdf: 
 
 
 
 
Losartan as anti-inflammatory therapy to augment F508del CFTR recovery 
 
PROTOCOL 
VERSION 5.0 dated February 1, 2019 
NCT03206788 
 
Principal Investigator:  
Matthias Salathe, MD 
Chair, Internal Medicine 
University of Kansas Medical Center, 
 
Email: msalathe@kumc.edu 
Office: 913 588 6000 
 
Sponsor:  
 
 
Matthias Salathe, MD 
Chair, Internal Medicine 
University of Kansas Medical Center, 
 
Email: msalathe@kumc.edu 
Office: 913 588 6000 
 
 
Co-PIs:   
 
 
Maria Gabriela Tupaychi-Ortiz, MD 
Director of the Adult Cystic Fibrosis Program 
University of Miami School of Medicine 
Office: (305)243-5545 
Email: mtupayachiortiz@med.miami     
   
 
 
  Elizabeth Kramer, MD 
Research Director, Division of Pulmonary Medicine 
Professor, UC Department of Pediatrics 
Cincinnati Children’s Hospital Medical Center 
Office 513-636-4654     
Email Elizabeth.Kramer@cchmc.org  
 
 
William T. Harris, MD 
Assistant Professor Pediatric Pulmonology 
University of Alabama at Birmingham 
Office: 205-939-9583 
Fax: 205-975-5983 
Email: tharris@peds.uab.edu 
 
 
 
Funding:  
 
 
Cystic Fibrosis Foundation 
 
 


 
 
Background: The life span of patients with Cystic fibrosis (CF) continues to be shortened by progressive lung 
disease. CF can be caused by ~2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene. These mutations can be, even though imperfectly, classified into 5 groups, permitting the development of small 
molecules that rescue group-specific CFTR mutants. These small molecules made remarkable impacts on patients. 
The CFTR potentiator ivacaftor (Kalydeco™), approved by the FDA mainly for class III mutations, has shown 
improvements in ion transport (large decrease in sweat chloride), clinical outcome (increase in FEV1 and weight, 
decrease in exacerbation rates), and quality of life (1). However, ivacaftor did not immediately eliminate airway 
inflammation, despite improvement in CFTR conductance, at least not within 12 month (2). Later time points may 
indicate anti-inflammatory effects. However, airway inflammation is associated with morbidity in CF (reviewed in 3) 
and additional anti-inflammatory treatment options are needed.  
F508del, a class II mutation, is the most common mutation in the US CF population. The FDA recently approved 
Orkambi™ and Symdeco™, both combinations of a corrector and potentiator (lumacaftor/tezacaftor and ivacaftor), to 
reduce exacerbations in F508del homozygous patients. However the effect of both medications on lung function and 
sweat chloride was modest at best (4-6). One explanation for this suboptimal efficacy in vivo could be the ongoing 
airway inflammation as outlined above. In this context, TGF-β1 has been identified as a disease modifier in CF (7). 
Increased production of TGF-β1 is common in CF airways and has been associated with worse pulmonary outcome 
(8,9). In particular, TGF-β1 has been shown to decrease the ability of lumacaftor to rescue CFTR function and airway 
surface liquid (ASL) volume in vitro (10,11). Since tezacaftor has a similar mode of action compared to lumacaftor, 
it is not surprising that TGF-β1 also decreases the ability of tezacaftor to rescue CFTR currents in vitro (our own 
published observations). TGF-β1-associated inflammation also decreases the function of other ion channels important 
for ASL volume regulation: Calcium activated chloride channels (CaCC) and the apical potassium channel BK (11,12). 
We therefore propose that airway inflammation, especially via TGF-β1, leads to a lower CaCC and BK activity, 
worsening mucociliary dysfunction in CF. Importantly, TGF-β1 also causes a decreased ability of lumacaftor to 
rescue F508del CFTR to the membrane, explaining at least part of the suboptimal efficacy of correctors in inflamed 
airways.  
 
 IN VIVO PRELIMINARY EVIDENCE FOR THE ABILITY OF LOSARTAN TO REVERSE MUCOCILIARY DYSFUNCTION IN SHEEP    
We developed a large animal model, at least in part simulating CF airway disease by exposing sheep to an inhalation 
challenge with CFTRinh172 and human neutrophil elastase (HNE) or TGF-β1 (to produce inflammation). Either 
combination led to a significant reduction in tracheal mucus velocity (TMV), a surrogate marker of mucociliary 
clearance. Importantly, inhaled losartan reversed the CFTRinh172+HNE- or CFTRinh172+ TGF-β1-induced 
mucociliary dysfunction in vivo (Fig. 1). 
 
Figure 1. Effects of losartan on a 3-day challenge model of mucociliary dysfunction. Left: 3-day challenge with CFTRinh172 (10 mg) and HNE (2380 mU) 
leads to prolonged (at least lasting 48h) mucociliary dysfunction (reduction in TMV) in sheep. Inhaled losartan (50 mg) reversed TMV decreases (solvent of 
losartan had no effect). Right: Challenge with CFTRinh172 and TGF-β1 (25 µg) reduces TMV that is again rescued by inhaled losartan (50 mg). All n = 3. 
Mean ± SE are shown. 
 
ADDITIONAL PRELIMINARY DATA  
Additional preliminary data in patients show that Orkambi™ alone does not improve CFTR function in vivo as 
measured by nasal potential difference (NPD), possibly because of ongoing inflammation in CF patients. Given the 
small changes in sweat chloride, the same is true for Symdeco™. In vitro data show that: 
• Losartan reverses the detrimental effects of TGF-β1 on ASL volume  
• Losartan reverses the detrimental effects of TGF-β1 on CaCC and BK currents  
• Losartan reverses the detrimental effects of TGF-β1 on lumacaftor-mediated F508del CFTR current recovery 
• TGF-β1 has detrimental effects on tezacaftor-mediated F508del CFTR current recovery  
• Decreases in ATP-induced PD are a measure of both CaCC and BK dysfunction.  


• Losartan improved mucociliary dysfunction in a sheep model with CFTR inhibition and airway inflammation  
These data make a compelling case for testing losartan as an anti-inflammatory medication in patients homozygous 
for F508del to improve the effects of Orkambi™ or Symdeco™ therapy on ion transport. Losartan will be given at 
least 12 weeks to assure that possible anti-inflammatory effects will have a chance to change the airway environment, 
since 4 weeks of treatment was insufficient in previous trials with other anti-inflammatory medications. 
Study Design and Methods 
We propose to conduct a proof of concept clinical trial to test if administration of losartan augments CFTR 
function in vivo in patients who are on Orkambi™ or Symdeco™. The goal of our pilot clinical trial is to examine 
the ability of losartan on CFTR (primary hypothesis) and possibly BK rescue/augmentation (secondary hypothesis) in 
patients homozygous for F508del on Orkambi™ or Symdeco™ therapy. The additional benefit for BK channels could 
be important but is harder to measure in vivo. Towards this end, however, we will assess CaCC/BK activity together 
as the response to ATP during NPD measurements, even though this is not an accurate reflection of either channel on 
its own. 
Note that ATP-induced changes in NPD in CF patients are higher than in normal subjects because in vitro data 
show that this response is increased in the absence of BK activity. Thus, the expectation here is that the rescue 
of BK activity with losartan will DECREASE NPD responses to ATP.   
 
Primary hypothesis: Losartan treatment for 12 weeks will improve CFTR conductance as measured by NPD in 
patients on Orkambi or Symdeco therapy. We expect that compared to placebo, ∆NPD in response to 0 Cl-
/isoproterenol will change by more than -4 mV using the most polarized nostril each time. 
 
Secondary hypotheses: Losartan treatment for 12 weeks will improve BK and CaCC activity as assessed by a 
decrease of changes in NPD to ATP exposure. Furthermore, losartan will reduce nasal cytokine levels and systemic 
inflammatory markers. 
 
Study plan: Details are seen in Figure 2 and the study table. Briefly, 36 patients with CF, > 12 years of age, who 
are homozygous for F508del and have been on treatment with Orkambi™ or Symdeco™ for at least 3 months will be 
recruited for this trial. This trial will be randomized 1:1 with placebo (n=18 for each group). After signing informed 
consent at the screening visit, we will perform spirometry, determine sweat chloride, take blood (see below), and test 
for pregnancy where applicable. Since losartan has teratogenic effects, we will enforce strict birth control in female 
participants (see Potential Risk section.)    
Eligible patients will complete visits as outlined below. Quality of life will be assessed by CFQ-R (CF quality of 
life questionnaire - revised, 13). NPD will use standard protocols and so will nasal cell harvest (see below for 
assessments). Cytokines will be measured from nasal fluid recovered by Leukosorb filter paper (14). There will be 
two visits for these different nasal assessments to assure that nasal cell fluid and cell collection will not influence NPD 
and vice versa. After assessing baselines, a daily dose of 50 mg losartan or placebo will be started. If patient’s weight 
is less than 55 kg dose will be adjusted to a daily dose of 25 mg losartan or placebo A safety follow up phone call will 
occur after 7 days of treatment (± 2 days) and the losartan dose (or placebo) increased to 25 mg or 50 mg twice a day 
as higher dose is likely needed to get anti-inflammatory effect in airways if present. Since this trial assesses anti-
inflammatory effects of losartan (and lack of placebo), the total duration will be 14 weeks to achieve at least 12 weeks 
of treatment with the higher dose of losartan (or placebo).  
 
Endpoints 
• Primary endpoint 
• ∆NPD with 0 Cl-/isoproterenol as a measure of CFTR activity in losartan treatment compared to placebo 
(15), done according to standard procedures (16); for power calculation, see below. All traces will be read 
blinded at the Cincinnati Children’s Hospital Medical Center and University of Alabama at Birmingham 
for the active or placebo arm. 
• Secondary endpoints 
• CaCC and BK activity as measured by change in NPD upon ATP application (see above). 
• Change in sweat chloride concentration 
• FEV1 (absolute and relative changes) 
• Changes in serum inflammatory markers (hsCRP, WBC including absolute neutrophil count, % PMNs, 
SAA, calprotectin, GM-CSF, TGF-β active and total) 
• Nasal cytokine changes (IL-1β, TGF-β active and total, IL-6, IL-8 IL-13) 
• Quality of life questionnaire (CFQ-R) 
• Blood levels of losartan, EXP3179, and EXP3174 (17,18)  
• LRRC26 mRNA (correlates with BK activity in vitro) and TGF-β mRNA expression in nasal cells by 
qPCR (while some contamination with other cells is possible, “purification” with for instance cell sorting 


is not feasible given the small number of cells; we will assess purity after cytospin with epithelial and other 
cell markers using immunofluorescence).  
 
Intervention 
• After establishing baseline parameters, patients will be started on oral losartan, 50 mg or 25 mg (based on 
patient’s weight) daily in am for 1 week before dose will be increased to twice daily in am and pm. If participant 
present any relevant AE related to the study medication, at the PI discretion, the dose will not be increased to 
BID and participant will be withdrawn from the study. . 
• Trial is randomized 1:1 to active drug and placebo (pharmacy will provide drug and placebo; randomization 
occurs through the biostatistics core at University of Miami).  
 
Measurements 
1. Visits will occur for screening, baseline and then treatment according to the attached schedule.  
2. 
Sample collection will include NPD, sweat chloride, nasal cell and nasal fluid collection, spirometry, CFQ-R, serum 
C-reactive protein (hsCRP), WBC (including absolute neutrophil count, % PMNs), serum alpha-SAA, calprotectin, 
and GM-CSF. In addition, losartan and EXP3179/3174 levels will be assessed (17,18).. Nasal airway epithelial cells 
will be taken by brush for mRNA expression levels of TGF-β and LRRC26. Exacerbation assessment, defined 
according to the TRAFFIC/TRANSPORT studies (19) will occur during study visits and unscheduled visits if needed 
 
 
Inclusion criteria:  
• CF patients homozygous for F508del and on current treatment with Orkambi™ or Symdeco™  for at least 
3 months 
• Age >12 years 
• FEV1 ≥ 40% of predicted  
 
Exclusion criteria 
• When enrolling female patients 
o Not willing to adhere to strict birth control (combination of two methods) 
o Pregnancy  
• History of intolerance to angiotensin receptor blockers (ARBs) 
• Treatment with ACE inhibitor  
• Regular use of NSAIDs or potassium supplementation, treatment with aliskiren, or on anticoagulation 
• Oral corticosteroid use within 6 weeks 
• Exacerbation requiring treatment within 4 weeks 
• Current treatment for mycobacterial infections 
• Significant hypoxemia (oxygen saturation <90% on room air and rest or use of continuous oxygen 
treatment), chronic respiratory failure by history (pCO2 > 45 mmHg), clinical evidence of cor pulmonale 
• Untreated arterial hypertension (systolic blood pressure >140 mm Hg, diastolic blood pressure > 90 
mmHg) 
• Blood pressure less than 90 mm Hg systolic while standing 
• Cardiac, renal (creatinine 1.5 times normal limit), hepatic (LFTs > 3x normal upper limit), neurological, 
psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in study 
• Known renal artery stenosis 
• Concomitant airway disorders other than CF, such as ABPA. 
• Subjects with prior thoracic surgery 
The visits are detailed in the attached table. The timeline and randomization is given in Figure 2 below.  
 
Measures of Compliance: This will be accomplished in two ways: analysis of blood levels of losartan and the 
metabolites EXP3179/EXP3174; pill count (patients will bring their medication supply to the visits).  
 
Timeline: We will start up the trial in April 2017 with database creation for data capturing. We expect to start 
enrollment within 3 months. We expect to enroll each year 18 patients and be able to publish the results by the end of 
the 3.5-year funding request.  


 
Other issues: Efficacy and safety are addressed in the DSMB section. Data collection will occur by clinical research 
coordinators. Data monitoring and quality control will be provided by the Clinical Research Operations & Regulatory 
Support (CRORS) monitoring group at the University of Miami. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Timeline and interventions. The enrollment and interventions are depicted graphically for an easier understanding. More detailed visit procedures 
are provided in the attached table.  
 
 
Study Procedures 
Once informed consent is signed, the subjects will undergo the following procedures: 
 
General and questionnaire: Data collected will include demographics, clinical symptoms, CFQ-R, and blood work. 
We will also collect history of other medical conditions, medications, and exacerbation history. 
 
History and physical examination will be performed including vital signs and body mass index (BMI) will be recorded.  
 
Pulmonary function testing will be performed according to American Thoracic Society recommendations. Participants 
will be asked to refrain from using short-acting bronchodilator drugs for at least 4 hours before testing and not take 
any long acting bronchodilator in the morning. Height, weight and oxygen saturation will be measured prior to these 
tests. 
 
Blood and urine samples:  Urine pregnancy test will be performed at all site visits. If positive, confirmation with serum 
pregnancy test will be obtained. Blood test for liver and renal function, inflammatory markers and blood levels of 
losartan and the metabolites EXP3179/EXP3174 will be drawn. A total of 30 cc (2 tablespoons) of blood will be collect 
at Visit 1 and visits 4, 5, and 7.   
 
NPD measurement will be performed according to standard procedures (latest SOP of the Therapeutic Development 
Network of the CF Foundation). Double lumen nasal catheters with an external diameter of 2.5 mm will be used for 
measurements. One lumen will be filled with freshly prepared agar; the other lumen will be used for perfusion with 
different solutions. The agar catheter and subcutaneous bridges (metal butterfly needle system) will be made prior to 
use by warming 3% agar gel and injecting the solution into the catheter. They will be attached to 3M KCl/calomel 
reference electrodes (Baxter; Deerfield, IL) and connected to a bioamplifier system (AD Instruments; Colorado 
Springs, CO) for measuring and recording. The initial potential difference (PD) will be measured at the anterior tip of 
the inferior meatus. Then, the basal PD will be measured at various distances within the inferior meatus in each nostril. 
The nasal catheter will be fixed at the most negative potential in one nostril, and the test will be initiated using perfusion 


with Ringer solutions until a stable value (± 0.5 mV over 30 s) is obtained. Then, the nose will be rinsed with different 
solutions containing amiloride (to block ENaC), no chloride (stimulate flow through CFTR), and isoproterenol 
(activate CFTR). Finally, we will use ATP to increase the intracellular calcium concentration and activate CaCC. 
These tests will be repeated in the other nostril. De-identified NPD traces will be read at a central laboratory (Dr 
Clancy’s lab at Cincinnati Children’s Hospital Medical Center (CCHMC) and Dr Harris at University of Alabama at 
Birmingham (UAB)) blinded for the active or placebo arm.   
 
Nasal sample collection: Nasal sample will be collected using Leukosorb as previously reported (14). In addition, we 
will obtain a small amount of nasal epithelial cells to measure TGF-ß by qPCR. De-identified samples will be sent to 
the Human Research Laboratory at University of Kansas Medical Center (KUMC) for analysis.  
 
Sweat test. The sweat chloride test is a standard diagnostic tool for CF, serving as a biomarker of CFTR activity. Sweat 
samples will be sent to a central laboratory (Dr. Clancy’s lab at CCHMC) for testing and interpretation of results. 
Individual sweat chloride test results will not be disclosed to the participants, with the exception of screening results. 
Specific instructions for collection, handling, processing, and shipping of sweat chloride samples to the local 
laboratory will be according to CFF guidelines. 
 
 
List of assessments (see Appendix 1) 
 
 
EXPECTED RESULTS, LIMITATION AND DIFFICULTIES 
Given our preliminary data in vitro and in vivo, we expect that losartan increases functional CFTR recovery by 
Orkambi™ or Symdeco™ and possibly CaCC and BK function. We expect to see meaningful improvements not only 
in NPD but also in sweat chloride as well as decreases in hsCRP levels and other inflammatory markers locally and 
systemically (if elevated). We also expect improvements in CFQ-R scores.  
The investigators have experience with executing clinical trials and with the measurements of the proposed 
endpoints. It is clear that there are several limitations: Even though power calculations (see below) indicate that the 
sample number should be sufficient to detect meaningful changes at least in the primary endpoint, the NPD and 
secondary endpoint signals need to be high enough to detect changes. Given the in vitro data, we are moderately 
confident that we will be able to detect these if present. The duration of the trial could be an issue (attrition), but our 
experience with adherence in clinical trials of this duration with CF patients indicate that this is not a limiting factor. 
We believe that allowing losartan to work as an anti-inflammatory for 3 months is important to counteract chronic 
inflammation in the airways. We will collect data that will indicate whether or not such an anti-inflammatory action 
actually occurs (even locally) and whether it is related to CFTR conductance changes. Secondary endpoints are purely 
exploratory however. If only trends are established, the data will lend itself to the design of a larger trial to fully 
explore the anti-inflammatory actions of losartan in CF patients.  
 
Potential Benefits of the Proposed Research to the Subjects and Others 
There is no direct benefit to the subjects for participating on this study. Benefits for others may arise from data obtained 
in these studies to prevent and/or treat mucociliary dysfunction. 
At the conceptual level, this project innovates by addressing airway inflammation with known properties of the 
commonly used, well tolerated, FDA approved medication losartan. At the therapeutic level, this project has the 
potential to add medical approaches for CF patients: the project could identify ARBs, and particularly losartan, as a 
“low hanging fruit” for treating CF patients by inhibiting TGF-β1 signaling to try to restore mucociliary transport and 
improve ∆F508 CFTR restoring therapies. This approach is innovative since it avoids lengthy toxicity studies of new 
molecules and can be introduced into the clinic rapidly if successfully tested in clinical trials. Furthermore, the anti-
inflammatory metabolite of losartan could stimulate the development of other, more potent anti-inflammatory 
molecules, and used for other airway diseases.  
 
Recruitment and Informed Consent: Each site will recruit approximately 9 patients at the CF clinics. The study and 
informed consent form will be approved by the University of Miami’s IRB. University of Miami IRB will serve as 
Central IRB and other Relaying IRBs will be the CCHMC, KUMC and UAB. Subjects will have sufficient time to 
meet with the PI and co-PIs to address all their questions about the research.  
 
Protection of Confidentiality: No personal identifiers will be collected and each patient’s data will be coded There 
will be no names or other identifiers recorded on study data guaranteeing the success of these confidentiality measures 
(we will know age, gender and CF mutations). 
 


STUDY DRUG: LOSARTAN  
Cozaar, the commercial form of losartan is an FDA-approved ARB widely prescribed for treatment of 
hypertension, heart failure, and for renal protection in patients with diabetes. Losartan and matching placebo (25 mg 
or 50 mg pills/ placebo) will be compounded at each site by the  research pharmacist  and distributed to the subject 
based on the randomization table provided by the Biostatistician at University of Miami. Losartan/placebo will be 
given to the subjects by the PI or study coordinators free of charge. FDA has granted IND exemption for this study. 
The research pharmacist is responsible for maintaining accurate study drug accountability records throughout the 
study. Dose will be adjusted based on participant’s weight at visit 1 as following: if participant’s weight is < 55 kg, 
participant will be randomized to either 25 mg or placebo.  If participant’s weight is ≥ 55 kg, participant will be 
randomized to either 50 mg or placebo. 
Each dispensing of study drug will be documented in the subject’s study records and in the drug accountability log. 
Subjects will return all unused study drug for drug accountability. Study drug will be destroyed at the research site as 
per the Institution regulations at the end of study. 
 Research pharmacists, UM biostatistician core and the assign unblinded monitor will be unblinded. Emergency 
plan for unblinding will be discussed with PI with consulting with the medical monitor and DSMB if necessary.  
 
STATISTICS AND POWER ANALYSIS  
Randomization: Upon eligibility, a statistician randomizes all subjects in a 1:1 ratio to the placebo or losartan 
treatment group and informs the research pharmacy. Participants will be stratified by site during randomization.  
Design: The basic study design consists of random assignment of patients to one of two treatment arms: losartan 
or placebo. Data will be collected at the visits as outlines above.  
Analysis: Primary endpoint: A t-test will be used as preliminary data analysis. For the formal analysis, mixed 
effects models model will be used for analysis to accommodate the paired measures nature of the design, as well as 
missing values under the MAR assumption. We will determine the final analytic approach based on the final available 
data. Examination of baseline differences on key variables between subjects remaining and those lost-to-follow-up 
will also be conducted. The first set of analyses will not adjust for dropouts. Only cases with complete data will be 
included. 
Secondary endpoints: Prior to analysis, we will investigate the distributional properties of the defined outcome 
measures - such as CaCC/BK activity, change in sweat chloride concentration, FEV1, changes in serum inflammatory 
markers, etc. Necessary transformations such as logarithmic or square root will be applied to satisfy normality 
assumptions if necessary. Baseline values of all variables will be examined, and estimates of baseline means and 
changes over time will be provided. The statistical analysis will consist of descriptive statistics associated with 
outcome measure (mean change or mean difference pre and post treatment) for two treatments. Means at baseline, 6 
and 13/14 weeks, for each outcome, as well as the change over time will be provided, as well as the corresponding 
estimates of variability, and 95% confidence intervals will be constructed. t-tests for comparisons of the changes over 
the period between treatments will be conducted. However, the primary focus for this analysis is to obtain reliable 
estimates of the mean changes and variability, which will be useful for designing further investigation focused and 
specifically powered for comparing these outcomes. P-value will be significant if < 0.05. All tests will be two-tailed. 
The SAS statistical software package version 9.3 (Cary, NC) will be used for all statistical analyses.  
Consultant Arrangements  
Biostatistics support will be provided by Dr. Hua Li from the biostatistics core. The presented statistics and power 
analysis was developed with Dr. Hua Li. A specialized lab will provide blood level measurements of losartan and its 
metabolites in the blood (Dr. Peloquin at the University of Florida). 
 
Data management  
Data collected will include demographics, clinical symptoms, CFQ-R, pulmonary function tests and NPD. Samples to 
be collected include nasal fluid (Leukosorb) and nasal cells at the beginning, during and at the end of the study. We 
will obtain blood for safety reasons (liver and renal function), for evaluation of an inflammatory marker (CBC w/ 
differential; CMP; CPK, CRP and other inflammatory markers). Blood for levels of losartan and metabolites (before 
next morning dose) will be also collected at the end of each treatment phase. 
No personal identifiers will be collected and each patient’s data will be coded. Data will be captured at secure password 
protected website (Red-Cap). Sites will be granted access to this database.  
Monitoring will be provided by Clinical Research Operations & Regulatory Support (CRORS) monitoring group 
at the University of Miami. 
.  
 
 
Potential Risks  


All procedures are performed during this study are routine procedures and are associated with minimal risks.  
Pulmonary Function Testing (Spirometry) is a routine clinical procedure with few risks. Patients are coached to make 
repeated forceful breathing efforts. The subjects might have chest soreness. Unusually, subjects may become 
lightheaded during these efforts. We will minimize this risk by having the PFT done in a sitting position.  
NPD measurement: is a non-invasive method with minor risks and will be performed according to standard procedures 
(21-25).  
Minor risks include swallowing and aspiration of the solution used for rinsing the nose. Having the patient bending 
the head forward will minimize this risk, so that the solution is dripping out of the nose and not in the pharynx. The 
perfusion rate will be set at 5 ml/min, indicating that the nose will be rinsed with low volumes. Even in case of 
accidental swallowing or aspiration, there are limited risks of a severe reaction, even in a respiratory-wise impaired 
individual. Amiloride is a diuretic medication and can increase urine production when given in a higher dose, which 
is not expected here as the used dose is low and systemic absorption is not anticipated. Isoproterenol is a β-mimetic 
and can lead to tachycardia, hypertension and migraine. The dose used is low and the systemic absorption negligible. 
Other potential side effects include nosebleed, runny nose and coughing. For the study, a subcutaneous insertion of a 
butterfly needle is required, which brings a minimal risk of bruising, bleeding and infection. The butterfly is only used 
as a control electrode. No medications are injected through it into the skin or vascular system.   
Nasal sample collection and cell sampling: this procedure is routine and is sometimes associated with an unpleasant 
feeling due to the use of the Leukosorb filter, itching and coughing. Cell sampling can cause a mild discomfort and a 
mild nosebleed due to brushing.  
Phlebotomy: The risks from blood draw from a vein are minimal but include discomfort at the site of puncture, possible 
bruising around the puncture site, rarely an infection, and uncommonly, fainting from the procedure. Blood draws will 
be performed with as much care as possible to minimize local complications. Subjects will be sitting during the process 
for their comfort and will be asked not to look directly at the site of blood draw.   
Treatment with losartan (IND exemption for CF approved): Losartan is an FDA-approved ARB widely prescribed for 
treatment of hypertension, heart failure, and for renal protection in patients with diabetes. The doses proposed in this 
study are well tolerated by non-hypertensive patients without significant effect on blood pressure. The most common 
side effects are fatigue and dizziness.  Serious adverse events that are rare include angioedema, hypotension, renal 
dysfunction or failure, blood dyscrasias, hepatitis, or rhabdomyolysis (clinical assessment of muscle pain). The 
following should lower the risks to the subjects: The first dose of medication will be administered in the clinic and the 
patient observed for two hours with blood pressure monitoring. Subjects with hyperkalemia, renal dysfunction, or who 
are taking potassium supplements will not be enrolled into the study. Participants will be given written descriptions of 
potential side effects and what to do. For example, mild postural hypotension can be minimized by getting up slowly 
and maintaining adequate hydration. Skin rashes, palpitations or other moderate or severe adverse events (interference 
with usual daily activities) without other clear explanation should warrant immediate cessation of treatment and 
notification of study personnel. There are no drug interactions between losartan and Orkambi™. Nor are there relevant 
drug interactions between losartan and or Symdeco™ (by Vertex’ drug interaction guidance in their 661 and later 
clinical trials).  
Sweat chloride collection: this is a routine procedure in a CF center and uses a macroduct to collect sweat secretions 
stimulated by pilocarpine iontophoresis, done according to CFF and CLSI guidelines. The test is well tolerated. A 
small risk of complications includes mild reddening of the skin. Damage to the skin, such as blistering or burns, occurs 
very infrequently and this risk can be minimized by careful attention to technique.  
Questionnaires, Health History and Physical Examination acquire information that is routinely collected. No 
significant physical risks arise from these procedures. There is always the risk of psychological distress and breach of 
confidentiality. In order to minimize this risk, electronic medical records are held in HIPAA compliant password-
protected databases, and written information is stored in locked files or file-rooms when not attended by study 
personnel.  
  
Pregnancy 
Female subjects will have to adhere to strict birth control. They will be counseled to immediately inform the 
Investigator if there was non-compliance or if pregnancy occurs during study treatment and within 90 days after 
the last dose of the study drug. 
If a female subject becomes pregnant while participating in the study, study drug must be immediately and 
permanently discontinued. Positive pregnancy test results, for minors under the age of 18, will be shared with parents. 
The subject will be counseled and if pregnancy is continued until delivery, the subject if followed and the infant for 1 
year after the birth, provided informed consent/assent is obtained. A separate informed consent form will be provided 


to explain these follow-up activities. The investigator must notify the DSMB and IRB within 24 hours of the site's 
knowledge of the subject's pregnancy and other 
agencies as by law. Pregnancy itself does not constitute an AE.  
 
 
Adequacy of Protection Against Risks 
Recruitment and Informed Consent: Subjects will be recruited from the respective CF clinics. First, the subjects will 
be briefed about the study and if interested will be invited to come on a separate day with ample time just to discuss 
the study objectives, procedure risks and benefits with the study investigators. The study and informed consent form 
will be approved by the University of Miami’s IRB. Subjects will have sufficient time to meet with the co-PIs to 
address all their questions about the research and take the informed consent home to discuss with family.  
Protection against Risk: General approaches for each procedure to minimize risk were described above. We will 
carefully select subjects that can tolerate the procedures of the study. All participant sites are fully equipped to handle 
possible fainting and other, more serious types of medical emergencies (CPR cart physicians and study staff are trained 
in BLS and ACLS) to handle any potential emergency.  
All research data will be secured using password in Universities approved databases. Access to these data will be 
restricted to the research staff only.  
 
Vulnerable Populations: The study intends to enroll subjects from the following “vulnerable” categories: minor. In 
this case, subjects will be asked to sign the IRB approved assent form. 
 
Potential Benefits of the Proposed Research to Human Subjects and Others 
Subjects will likely not receive any long-term benefit from participating in this project, but might experience a potential 
benefit from participating (improved clearance). They always have the alternative not to participate. By participating, 
they will allow the performance of the proposed studies. The studies have the potential for an overall benefit in 
advancing knowledge of the disease studied. Because the study drug is usually well tolerated, the risks to subjects are 
reasonable in relation to the anticipated benefits, including knowledge to be gained. 
Importance of the Knowledge to Be Gained 
The proposed clinical research has the potential of providing important information that could be used as base for 
future studies and eventually change the way CF is treated and improving not only the quality of life of patients with 
CF but also their lung function, at least in combination with other treatments. If the study is negative, we will have 
gained improved understanding of why and might be able to deliver these kind of medications via a different route in 
vitro and in vivo.  
Communication between sites 
There will be several lines of communications established between the sites. The investigators, Drs. Salathe, Kramer, 
Harris and Tupayachi-Ortiz will have monthly teleconference meetings to set up the study at all sites including use of 
case report forms (CRFs) and databases; establishing route of communications and shipping by pharmacy etc. When 
the trial is ongoing the meetings will be at least bi-monthly to discuss the progress of the study and bring up issues 
that need resolution. More frequent informal communications will occur via email and phone calls if necessary. The 
conference calls will be attended by additional members of the team as needed to resolve any issues. Cystic Fibrosis 
Foundation Therapeutics (CFFT) will serve as DMC and DSMB on this study. 
 
Safety Reporting and Monitoring Plan 
Data monitoring plans will be implemented as follows: 
The study will be monitored by Clinical Research Operations & Regulatory Support (CRORS) monitoring group 
at the University of Miami. 
3.  Monitoring will occur every 3 months or more frequently if needed.  
4. IND exemption for use of losartan in CF patients was granted by the FDA 
5. Safety monitoring will be done by the DSMB of the CFFT. 
6. Adverse Event Monitoring 


o Subjects will be carefully monitored for adverse events (AEs) and serious adverse events (SAEs). 
Adverse events will be assessed in terms of their seriousness, severity, and relationship to the 
administration of Losartan. 
o All adverse effects will be reported to the co-PIs and discussed with the monitoring group 
 If deemed severe the data will be shared with the DSMB. They will make the decision whether or 
not to stop the trial. 
 All SAEs will be reported to the DSMB and the appropriate agencies as required.  
 All adverse effects will be reported according to the rules to the FDA, the IRB and to the DMSB 
 
Definitions 
7. Adverse Event (AE): An AE is any untoward medical occurrence in a clinical study participant administered 
with a pharmaceutical product. The AE does not necessarily have to have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of an investigational product, whether or not 
considered related to the medicinal product.  
8. Unexpected AE: is any adverse drug event, which is not consistent with the current Losartan US Package Insert. 
9. Serious Adverse Event (SAE): A SAE is any untoward medical occurrence that at any dose: 
• results in death 
• is life-threatening 
• requires unanticipated in-patient hospitalization or prolongation of existing hospitalization 
• results in persistent or significant disability or incapacity 
• results in a congenital anomaly or birth defect 
• any significant medical event as per the investigator’s discretion 
 
Relationship of Adverse Event to Losartan 
The assessment of the relationship of an AE to the administration of study drug is a clinical decision based on all 
available information. An assessment of ‘No’ would include choices of “not related” or “unlikely related” in the 
following cases: 
1. The existence of a clear alternative explanation, or 
2. Non-plausibility (clearly an unrelated circumstance). 
An assessment of ‘Yes’ includes choices of “possibly related or “related” and indicates that there is a reasonable 
suspicion that the AE is associated with the use of the investigational drug. 
 
Factors to be considered in assessing the relationship of the AE to study drug include: 
• The temporal sequence from drug administration: The event should occur after the drug is given. The length 
of time from drug exposure to event should be evaluated in the clinical context of the event. We will 
consider a significant time interval up to 2 hours.  
• Underlying, concomitant, intercurrent diseases: Each report should be evaluated in the context of the 
natural history and course of the disease being treated and any other disease the subject may have (i.e. a 
pulmonary exacerbation) 
• Concomitant medication or treatment: The other drugs the subject is taking or the treatment the subject 
receives should be examined to determine whether any of them might be suspected to cause the event in 
question 
• Concurrent study procedures: Study procedures should also be considered as possible causes of an AE.  
In this study, the investigator will make a separate and independent assessment of every AE’s relationship not just to 
the study drug, but also to concurrent study procedures and to the subject’s pre-existing medical condition(s). 
A laboratory test abnormality considered clinically relevant, e.g., causing the subject to withdraw from the study, 
requiring treatment or causing apparent clinical manifestations, or judged relevant by the investigator, should be 
reported as an AE. Each event should be described in detail along with start and stop dates, severity, relationship to 
investigational product, action taken and outcome. 
Each AE should be followed up until resolution or stabilization as determined by the investigator. 
 


Severity of the Adverse Event 
The severity of AEs, except for AEs for exacerbations, should be graded as follows: 
• Mild – usually transient in nature and generally not interfering with normal activities 
• Moderate – sufficiently discomforting to interfere with normal activities 
• Severe – prevents normal activities. 
 
Pulmonary Exacerbation: A pulmonary exacerbation is defined as a new or change in antibiotic therapy (IV, inhaled, 
or oral) for any 4 or more of the following signs/symptoms: 
• Change in sputum 
• New or increased hemoptysis 
• Increased cough 
• Increased dyspnea 
• Malaise, fatigue, or lethargy 
• Temperature above 38°C (equivalent to approximately 100.4°F) 
• Anorexia or weight loss 
• Sinus pain or tenderness 
• Change in sinus discharge 
• Change in physical examination of the chest 
• Decrease in pulmonary function by 10% 
• Radiographic changes indicative of pulmonary infection 
 
Removal of Subjects from Study 
A subject withdrawal is defined as a discontinuation from the study for any reason. Subjects may withdraw or be 
withdrawn from this study for the following reasons: 
• At their own request or at the request of their authorized representative at any time for any reason 
• If, in the investigator's opinion, continuation in the study would be detrimental to the subject's well-being 
Also subjects must be withdrawn from the study for the following reasons: 
• Subjects with an occurrence of a concomitant disease, or any medical condition which, either because of its 
severity or duration or necessary change in treatment, contravenes the condition of the study or puts the 
patient at unnecessary risk or harm.  
• Subjects with an occurrence of an AE/SAE which in the opinion of the investigator and/or subject requires 
termination of treatment. For example, skin rashes, palpitations or other moderate or severe adverse events 
(interference with usual daily activities) without other clear explanation should warrant immediate cessation 
of treatment and notification of study personnel.  
• Subjects who are noncompliant with the protocol per the investigator’s discretion 
• Pregnancy 
• Severe CF exacerbation during the study as by investigators’’ discretion. 
Subjects who terminate the clinical study prematurely, either at their own request or on the recommendation of the 
clinical investigator, will be considered early terminations. Subjects who withdraw from the study will not be replaced. 
Subjects who are discontinued from the study will be requested to return for Early Discontinuation and perform 
procedures as for visit 8. 
 
 
 
 
 
Assessment of efficacy 
N/A 
 
 
 


 
Quality Control & Quality Assurance 
 
Monitoring of the study will be provided through the Clinical Research Operations & Regulatory Support (CRORS) 
monitoring group at the University of Miami. 
 
 
Ethics 
This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of 
Helsinki and that are consistent with the GCP and applicable regulatory requirements.  
 
The clinical protocol will be submitted to and approved by the UM IRB and will not be initiated until written 
notification of approval of this study has been received.  
 
IND: because this study will use a medication released on the market but not for this indication, IND exemption was 
granted for use of losartan in this population.  
 
Record Keeping 
Accurate and complete study records from all sites will be maintained and kept at storage facility (Iron Mountain) 
for a minimum of 6 years after completion of the study. 
 
ADMINISTRATIVE SECTION 
Protocol Amendments 
Any amendments to the protocol will be approved by the PI and co-investigators. All amendments will be 
submitted to the IRBs for review and approval prior to implementation unless the amendment details changes 
related to safety. 
 
Protocol Deviations 
The investigator will only make changes to the protocol procedures when necessary to protect the safety, 
rights, and welfare of the subjects. In such an event where protocol procedures are changed, the investigators 
are responsible for notifying the IRBs and the internal DSMB. 
In the event that an isolated, unforeseen instance occurs resulting in a protocol deviation, the investigators are 
to document this deviation and notify IRBs as by the rules of the University of Miami, the Cincinnati Children’s 
Hospital Medical Center, the University of Alabama, Birmingham and University of Kansas Medical Center.  
 
Case Report Form (CRF) 
All clinical data will be recorded on the CRFs for this study, including their electronics versions (Red Cap). 
 
Study Documentation and Records Retention 
The Good Clinical Practice guidelines issued by the Committee for Proprietary Medicinal Products state that 
“The investigator must arrange for retention in strict confidence of the subjects’ identification codes, names and 
addresses for at least 15 years after the completion or discontinuation of the trial.” Subjects’ files and other 
pertinent documentation (i.e., study protocol, signed informed consent forms, drug dispensing logs, 
correspondence, and other documents pertaining to the conduct of the study) must be kept for the maximum 
period permitted by the hospital or private office in accordance with the local requirements, but not less than 15 
years. 
 
Publication policy 
The results of this research will be disseminated to the scientific community. These results will include results of 
primary study outcomes and secondary analyses. Priorities in selecting journals and forums for publications 
submission will be given to peer-reviewed journals as well as presentations and publications of abstracts at national 
and international scientific meetings. All individuals who have made substantial intellectual, scientific and practical 


contributions to this research protocol and the manuscript should, where possible, be credited as authors; all 
individuals credited as authors should deserve that designation.  
 
ClinicalTrials.gov Registration  
This trial will be registered at ClinicalTrials.gov  
 
 
 
 


 
 
 
Literature Cited  
1. 
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Drevinek, P., Griese, M., McKone, E. 
F., Wainwright, C. E., Konstan, M. W., Moss, R., Ratjen, F., Sermet-Gaudelus, I., Rowe, S. M., Dong, Q., 
Rodriguez, S., Yen, K., Ordonez, C., Elborn, J. S., and Group, V. X. S. (2011) A CFTR potentiator in 
patients with cystic fibrosis and the G551D mutation. N Engl J Med 365, 1663-1672 
2. 
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., 
Mayer-Hamblett, N., Van Dalfsen, J. M., Joseloff, E., Ramsey, B. W., and Network, G. I. o. t. C. F. F. T. D. 
(2014) Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor 
in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190, 175-184 
3. 
Elizur, A., Cannon, C. L., and Ferkol, T. W. (2008) Airway inflammation in cystic fibrosis. Chest 133, 489-
495 
4. 
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., 
Davies, J. C., De Boeck, K., Flume, P. A., Konstan, M. W., McColley, S. A., McCoy, K., McKone, E. F., 
Munck, A., Ratjen, F., Rowe, S. M., Waltz, D., Boyle, M. P., Group, T. S., and Group, T. S. (2015) 
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 373, 
220-231 
5. 
Boyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, 
D., Patel, N. R., Rodman, D., and group, V. X. s. (2014) A CFTR corrector (lumacaftor) and a CFTR 
potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a 
phase 2 randomised controlled trial. Lancet Respir Med 2, 527-538 
6. 
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., 
Ingenito, E. P., McKee, C., Lu, Y., Lekstrom-Himes, J., and Elborn, J. S. (2017) Tezacaftor-Ivacaftor in 
Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med 377, 2013-2023 
7. 
Drumm, M. L., Konstan, M. W., Schluchter, M. D., Handler, A., Pace, R., Zou, F., Zariwala, M., Fargo, D., 
Xu, A., Dunn, J. M., Darrah, R. J., Dorfman, R., Sandford, A. J., Corey, M., Zielenski, J., Durie, P., Goddard, 
K., Yankaskas, J. R., Wright, F. A., and Knowles, M. R. (2005) Genetic modifiers of lung disease in cystic 
fibrosis. The New England journal of medicine 353, 1443-1453 
8. 
Arkwright, P. D., Pravica, V., Geraghty, P. J., Super, M., Webb, A. K., Schwarz, M., and Hutchinson, I. V. 
(2003) End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and 
cytokine gene polymorphisms. Am J Respir Crit Care Med 167, 384-389 
9. 
Arkwright, P. D., Laurie, S., Super, M., Pravica, V., Schwarz, M. J., Webb, A. K., and Hutchinson, I. V. 
(2000) TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 
55, 459-462 
10. 
Snodgrass, S. M., Cihil, K. M., Cornuet, P. K., Myerburg, M. M., and Swiatecka-Urban, A. (2013) Tgf-beta1 
inhibits Cftr biogenesis and prevents functional rescue of DeltaF508-Cftr in primary differentiated human 
bronchial epithelial cells. PLoS One 8, e63167 
11. 
Sun, H., Harris, W. T., Kortyka, S., Kotha, K., Ostmann, A. J., Rezayat, A., Sridharan, A., Sanders, Y., 
Naren, A. P., and Clancy, J. P. (2014) Tgf-beta downregulation of distinct chloride channels in cystic 
fibrosis-affected epithelia. PLoS One 9, e106842 
12. 
Manzanares, D., Krick, S., Baumlin, N., Dennis, J. S., Tyrrell, J., Tarran, R., and Salathe, M. (2015) Airway 
Surface Dehydration by Growth Factor TGF-beta in Cystic Fibrosis is Due to Decreased Function of a 
Voltage-dependent Potassium Channel and Can Be Rescued by the Drug Pirfenidone. J. Biol. Chem. 290, 
25710-25716 
13. 
Quittner, A. L., Sweeny, S., Watrous, M., Munzenberger, P., Bearss, K., Gibson Nitza, A., Fisher, L. A., and 
Henry, B. (2000) Translation and linguistic validation of a disease-specific quality of life measure for cystic 
fibrosis. J. Pediatr. Psychol. 25, 403-414 
14. 
Dhariwal, J., Kitson, J., Jones, R. E., Nicholson, G., Tunstall, T., Walton, R. P., Francombe, G., Gilbert, J., 
Tan, A. J., Murdoch, R., Kon, O. M., Openshaw, P. J., and Hansel, T. T. (2015) Nasal Lipopolysaccharide 
Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness. PLoS One 10, 
e0135363 


15. 
Rowe, S. M., Liu, B., Hill, A., Hathorne, H., Cohen, M., Beamer, J. R., Accurso, F. J., Dong, Q., Ordonez, C. 
L., Stone, A. J., Olson, E. R., Clancy, J. P., and Group, V. X. S. (2013) Optimizing nasal potential difference 
analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR 
mutation. PLoS One 8, e66955 
16. 
Solomon, G. M., Konstan, M. W., Wilschanski, M., Billings, J., Sermet-Gaudelus, I., Accurso, F., 
Vermeulen, F., Levin, E., Hathorne, H., Reeves, G., Sabbatini, G., Hill, A., Mayer-Hamblett, N., Ashlock, 
M., Clancy, J. P., and Rowe, S. M. (2010) An international randomized multicenter comparison of nasal 
potential difference techniques. Chest 138, 919-928 
17. 
Grothusen, C., Umbreen, S., Konrad, I., Stellos, K., Schulz, C., Schmidt, B., Kremmer, E., Teebken, O., 
Massberg, S., Luchtefeld, M., Schieffer, B., and Gawaz, M. (2007) EXP3179 inhibits collagen-dependent 
platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on 
atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 1184-1190 
18. 
Kappert, K., Tsuprykov, O., Kaufmann, J., Fritzsche, J., Ott, I., Goebel, M., Bahr, I. N., Hassle, P. L., Gust, 
R., Fleck, E., Unger, T., Stawowy, P., and Kintscher, U. (2009) Chronic treatment with losartan results in 
sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. Hypertension 54, 738-743 
19. 
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., 
Davies, J. C., De Boeck, K., Flume, P. A., Konstan, M. W., McColley, S. A., McCoy, K., McKone, E. F., 
Munck, A., Ratjen, F., Rowe, S. M., Waltz, D., Boyle, M. P., Traffic, and Groups, T. S. (2015) Lumacaftor-
Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med  
 
 
 




Appendix 2 
 
CFQR Questionnaire: 
More information:  
http://qol.thoracic.org/sections/instruments/ae/pages/cfq-cfq-r.html 
 
 


SUMMARY OF CHANGES: Protocol 2.0 dated July 2017: 
 
This amendment is to make the following modifications on the protocol version 1.0 dated march 2017.   
 
1. Losartan and matching placebo (25 mg or 50 mg pills/ placebo) will be obtained from Hunt Valley Research 
Pharmacy (Cockeysville, MD) and distributed to the 3 sites, and not from University of Miami Research 
Pharmacy 
 
2. Dose will be adjusted based on participant’s weight at visit 1 as following:  If participant’s weight is < 55 kg, 
participant will be randomized to either 25 mg or placebo.  If participant’s weight is ≥ 55 kg, participant will 
be randomized to either 50 mg or placebo. 
 
3. Blood for levels of losartan and metabolites will be collected before next morning dose and 2 and 6 hours 
post dose) 
 
4. Monitoring of the study will be provided through the Clinical Research Operations & Regulatory Support 
(CRORS) monitoring group at the University of Miami. 
 
 


 
SUMMARY OF CHANGES Protocol 2.1 dated September 2017 
This modification is to make the following changes on the protocol version 2.0 dated July 2017.   
 
1. 
Inclusion criterion FEV1:  It was changed to FEV1 ≥40% of predicted. Upper limit was deleted. 
 
2. 
Study medication provider: To change study medication provider from Hunt Valley to Research 
Pharmacists at University of Miami, University of Alabama at Birmingham and Cincinnati Children’s 
Hospital Medical Center. New text on page 7: Losartan and matching placebo (25 mg or 50 mg pills/ 
placebo) will be compounded at each site by the research pharmacist  and distributed to the subject 
based on the randomization table provided by the Biostatistician at University of Miami. 
 
 
3. 
Destruction of the Study drug: New text on page 7: Study drug will be destroyed at the research site as 
per the Institution regulations at the end of study. 
 
4. 
Clarification about unblinded study team: New text page 7: Research pharmacists, UM biostatistician 
core and the assigned unblinded monitor will be unblinded.  
 
5. 
Clarification about plan of unblinding: New text page 7: Emergency plan for unblinding will be discussed 
with PI with consulting with the medical monitor and DSMB if necessary.  
 
6. 
Record Keeping:  6 years after study completion instead of 10 years. ( on page 13). 
 
7. 
Visit 3 time-window:  ± 2 days was deleted on table of assessment page 17. 
 
8. 
Version and date of the protocol were updated to version 2.1 dated September 2017 on page 1. 
 
 


 
SUMMARY OF CHANGES Protocol 3.0 dated April 2018 
This modification is to make the following changes on the protocol version 2.1 dated September 2017 
1. Added PI at University of Miami: Maria Gabriela Tupaychi-Ortiz 
2. Version and date of the protocol were updated 
3. Urine pregnancy test was added to all site visits.  
4. Asthma was delete from exclusion criteria list 
5. Positive pregnancy tests will be shared with parents for participants under 18 years of age.  
6. Table of assessments was updated to add urine pregnancy test at all site visits and dispensation of study drug.  
 
 


 
SUMMARY OF CHANGES Protocol 3.1 dated June 2018 
 
This modification is to include patients treated with Symdeko™ (tezacaftor) for more than 3 month on the study.  
Orkambi™ and Symdeco™ are both FDA approved combinations of a corrector and potentiator 
(lumacaftor/tezacaftor and ivacaftor), to reduce exacerbations in F508del homozygous patients. Tezacaftor has a 
similar mode of action compared to Lumacaftor. Symdeko™ information was added on the Background, Study 
Design, Inclusion criteria and on related sections of the revised protocol. 
There are no relevant drug interactions between losartan and Symdeco™ (by Vertex’ drug interaction guidance in 
their 661 and later clinical trials), therefore this modification doesn’t increase participant risks.  
 
 
 
 


 
 
 
SUMMARY OF CHANGES Protocol 4.0 dated August 2018 
 
This modification is to include University of Kansas Medical Center (KUMC) as a study site. Dr Matthias Salathe 
will serve as PI at KUMC.  
 
Co-PIs information were updated on page 1. 
 
Nasal Samples: De-identified samples will be sent to the Pulmonary Research Laboratory at KUMC for analysis. 
 
Number of participants per site: number was changed to 9 participants per site.  
 
 


 
SUMMARY OF CHANGES Protocol 5.0 dated February 2019 
 
This modification is to make the following changes on the protocol version 4.0 dated August 2018: 
1. Exclusion of NPD response to 0Cl/Iso > -6.6 mV was removed. 
2. Exacerbation requiring treatment within the past 6 weeks- changed to 4 weeks 
3. NTM exclusion criteria changed to: Current treatment for mycobacterial infections 
4. Added New schedule of the visits. Appendix 1 Study includes 6 site visits (visits 1,2,4,5,7 and 8) and 2 
phone calls (visits 3,3a and 6). Study duration and treatment phases still the same. 
5. Extend the timeline for publish the results by the end of the 3.5-year funding request instead 2.5 years.  
6. Blood and urine samples were modified to match new study procedures schedule as:  A total of 30 cc (2 
tablespoons) of blood will be collect at Visit 1 and visits 4, 5 and 7.   
7.   Secondary endpoints were changed to match new study procedures schedule as following: Means at baseline, 
6 and 13/14 weeks, for each outcome, as well as the change over time will be provided, as well as the 
corresponding estimates of variability, and 95% confidence intervals will be constructed. 
8. Early Discontinuation procedures were changed to match new study procedures schedule as following: 
Subjects who are discontinued from the study will be requested to return for Early Discontinuation and perform 
procedures as for visit 8.